Compare
Zomedica Corp. vs Bioharvest Sciences Inc. vs Verrica Pharmaceuticals Inc. vs Earth Science Tech, Inc.
| Latest fiscal year | Zomedica Corp. ZOMDF | Bioharvest Sciences Inc. BHST | Verrica Pharmaceuticals Inc. VRCA | Earth Science Tech, Inc. ETST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $32.03M | $34.51M | $35.58M | $35.70M |
| Revenue growth (YoY) | +17.4% | +37.0% | +370.2% | +7.8% |
| Gross margin | 67.7% | 59.3% (computed) | n/a | 71.4% |
| Operating margin | -263.4% | -16.2% | -34.2% | n/a |
| Net margin | -255.6% | -32.3% | -50.3% | 10.2% |
| Net income | -$81.86M | -$11.13M | -$17.89M | $3.63M |
| EPS (Diluted) | -$0.08 | n/a | -$1.68 | $0.012 |
| Operating cash flow | -$17.65M | -$7.23M | -$17.63M | $1.94M |
| Free cash flow | -$18.22M | -$9.58M | -$17.63M | $1.18M |
| Cash & equivalents | $9.02M | $23.02M | $30.15M | $796.8K |
| Total assets | $127.04M | n/a | $47.13M | $8.97M |
| Total liabilities | $11.64M | n/a | $22.39M | $1.93M |
| Shareholders' equity | $115.40M | $25.45M | $24.74M | $7.01M |
| Return on year-end equity | -70.9% | -43.8% | -72.3% | 51.8% |
| Shares outstanding | 979.95M | n/a | 17.18M | 291.32M |
Revenue, most recent five fiscal years
| Fiscal year | Zomedica Corp. | Bioharvest Sciences Inc. | Verrica Pharmaceuticals Inc. | Earth Science Tech, Inc. |
|---|---|---|---|---|
| Latest | $32.03M Ended 2025-12-31 | $34.51M Ended 2025-12-31 | $35.58M Ended 2025-12-31 | $35.70M Ended 2026-03-31 |
| 1 year earlier | $27.29M Ended 2024-12-31 | $25.19M Ended 2024-12-31 | $7.57M Ended 2024-12-31 | $33.12M Ended 2025-03-31 |
| 2 years earlier | $25.19M Ended 2023-12-31 | $12.67M Ended 2023-12-31 | $5.12M Ended 2023-12-31 | $11.95M Ended 2024-03-31 |
| 3 years earlier | $18.93M Ended 2022-12-31 | n/a | $9.03M Ended 2022-12-31 | $48.5K Ended 2023-03-31 |
| 4 years earlier | $4.13M Ended 2021-12-31 | n/a | $12.00M Ended 2021-12-31 | $14.1K Ended 2022-03-31 |